NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceuticals shareholders. Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in c
Related Questions
How will the acquisition by MannKind and the issuance of non‑tradable CVRs affect SCPH’s liquidity, shareholder voting rights, and overall valuation post‑transaction?
What is the total consideration per share, including the contingent value rights, and how does it compare to SCPH's current market price?
What are the specific regulatory and net‑sales milestones required for the CVRs to vest, and what is the likelihood of those milestones being met?